Ultimo aggiornamento :
19/11/2024
Immunosoppressore   Mycophenolate mofetil  
Iniezione
Soluzione orale
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità metodo di iniezione Bibliografia pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cellcept Australia, Austria, Canada, Colombia, Danimarca, Finlandia, Francia, Germania, Giappone, Gran Bretagna, Grecia, Irlanda, Italia, Lussemburgo, Messico, Norvegia, nuova Zelanda, Paesi Bassi, Polonia, Portogallo, Spagna, Stati Uniti d’America, Svezia, Svizzera, Ungheria
Micofenolato de mofetilo Spagna
Mycophenolate mofetil Belgio, Germania, Gran Bretagna
Bibliografia   Iniezione   Bibliografia : Mycophenolate mofetil  
tipo pubblicazione
1981 Rivista Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C.
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags.
Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982 Rivista Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 Rivista Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2192 Rivista Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247 Rivista Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728 Rivista Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828 poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Rivista Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299 Rivista Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M.
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.
Biomed Chromatogr 2019 ; 33, 7: e4529.
4528 Rivista Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4698 Rivista Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022

  Mentions Légales